Find Reports

Select Report Type

Reimbursement Review

Displaying 526 - 550 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
ulipristal acetate	Fibristal	ulipristal acetate	SF0528_Fibristal_RFA_complete_Nov_22_17.pdf SF0528_Fibristal_RFA_Report.pdf SF0528_Fibristal_PI_Submissions.pdf	Uterine fibroids (signs and symptoms)	Reimburse with clinical criteria and/or conditions	Complete	Jun 21, 2017	Nov 22, 2017	SF0528-000
Brexpiprazole	Rexulti	Brexpiprazole	cdr_SR0514_TBC.pdf SR0514_Rexulti_complete_Nov_24_17.pdf SR0514_Rexulti_CL_Report.pdf SR0514_Rexulti_PE_Report.pdf SR0514_Rexulti_PI_Submissions.pdf	schizophrenia	Reimburse with clinical criteria and/or conditions	Complete	Feb 3, 2017	Nov 22, 2017	SR0514-000
ocrelizumab	Ocrevus	ocrelizumab	SR0519_Ocrevus_RMS_complete_Nov-23-17.pdf SR0519_Ocrevus_RMS _PE_Report.pdf SR0519_Ocrevus_RMS_CL_Report.pdf SR0519_Ocrevus_RMS_PI_Submissions.pdf	multiple sclerosis, relapsing	Reimburse with clinical criteria and/or conditions	Complete	May 16, 2017	Nov 21, 2017	SR0519-000
insulin degludec	Tresiba	insulin degludec	SR0521_Tresiba_complete_Nov-22-17_e.pdf SR0521_Tresiba_CL_Report.pdf SR0521_Tresiba_PE_Report.pdf SR0521_Tresiba_PI_Submissions.pdf	Diabetes mellitus, Type 1 & 2	Reimburse with clinical criteria and/or conditions	Complete	May 31, 2017	Nov 20, 2017	SR0521-000
Tafinlar & Mekinist in com...	Tafinlar & Mekinist in combo	Dabrafenib & Trametinib in combo	pcodr_provfund_tafinlar_mekinist_nsclc.pdf pcodr_tafinlar_mekinist_nsclc_fn_rec.pdf pcodr_tafinlar_mekinist_nsclc_fn_cgr.pdf pcodr_tafinlar_mekinist_nsclc_fn_egr.pdf pcodr_tafinlar_mekinist_nsclc_in_rec.pdf pcodr_tafinlar_mekinist_nsclc_pagfdk.pdf pcodr_tafinlar_mekinist_nsclc_fdk_novartis.pdf pcodr_tafinlar_mekinist_nsclc_ptfdk.pdf pcodr_tafinlar_mekinist_nsclc_clfdk.pdf pcodr_tafinlar_mekinist_nsclc_coi-cl.pdf pcodr_tafinlar_mekinist_nsclc_coi-pt.pdf	Non-Small Cell Lung Cancer	Do not reimburse	Complete	Mar 31, 2017	Nov 2, 2017	PC0106-000
travoprost ophthalmic solution	Izba	travoprost ophthalmic solution	cdr_SR0516_Izba.pdf SR0516_Izba_complete_Oct-30-17.pdf SR0516_Izba_CL_Report.pdf SR0516_Izba_PE_Report.pdf	Glaucoma and ocular hypertension	Reimburse with clinical criteria and/or conditions	Complete	Mar 1, 2017	Oct 25, 2017	SR0516-000
abobotulinumtoxinA	Dysport Therapeutic	abobotulinumtoxinA	dysport-therapeutic-product-monograph.pdf SR0517_complete_Dysport_Therapeutic_ULS_Oct_26-17_e.pdf SR0517_Dysport_Therapeutic_CL_Report.pdf SR0517_Dysport_Therapeutic_PE_Report.pdf SR0517_Dysport_ULS_PI_Submissions_Consolidated.pdf	Upper limb spasticity	Reimburse with clinical criteria and/or conditions	Complete	Apr 24, 2017	Oct 24, 2017	SR0517-000
Darzalex for Multiple Myeloma ...	Darzalex	Daratumumab	pcodr_profund_10104_daratumumab_darzalex_mm_2ln_beyond.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_rec.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_cgr.pdf pcodr_daratumumab_darzalex_mm_2ndln_fn_egr.pdf pcodr_daratumumab_darzalex_mm_2ndln_in_rec.pdf pcodr_daratumumab_darzalex_mm_2ndln_pagfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_fdk_janssen.pdf pcodr_daratumumab_darzalex_mm_2ndln_ptfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_clfdk.pdf pcodr_daratumumab_darzalex_mm_2ndln_coi_pt.pdf pcodr_daratumumab_darzalex_mm_2ndln_coi_cl.pdf	Multiple Myeloma (second-line)	Reimburse with clinical criteria and/or conditions	Complete	Mar 3, 2017	Oct 5, 2017	PC0104-000
Lynparza for Ovarian Cancer (R...	Lynparza (Resubmission)	Olaparib	pcodr_profund_olaparib_lynparza_resub.pdf pcodr_olaparib_lynparza_resub_fn_rec.pdf pcodr_olaparib_lynparza_resub_fn_cgr.pdf pcodr_olaparib_lynparza_resub_fn_egr.pdf pcodr_olaparib_lynparza_resub_in_rec.pdf pcodr_olaparib_lynparza_resub_pagfdk.pdf pcodr_olaparib_lynparza_resub_fdk_astrazeneca.pdf pcodr_olaparib_lynparza_resub_ptfdk.pdf pcodr_olaparib_lynparza_resub_clinfdk.pdf pcodr_olaparib_lynparza_resub_coi_pt.pdf pcodr_olaparib_lynparza_resub_coi_clin.pdf	Ovarian Cancer	Reimburse with clinical criteria and/or conditions	Complete	Mar 17, 2017	Sep 20, 2017	PC0103-000
Rituxan for Acute Lymphoblasti...	Rituxan	Rituximab	pcodr_profund_rituximab_rituxan_all.pdf pcodr_rituximab_rituxan_all_fn_rec.pdf pcodr_rituximab_rituxan_all_fn_cgr.pdf pcodr_rituximab_rituxan_all_fn_egr.pdf pcodr_rituximab_rituxan_all_in_rec.pdf pcodr_rituximab_rituxan_all_pagfdk.pdf pcodr_rituximab_rituxan_all_fdk_hlroche.pdf pcodr_rituximab_rituxan_all_coi_clinician.pdf	Acute Lymphoblastic Leukemia	Do not reimburse	Complete	Feb 13, 2017	Aug 31, 2017	PC0102-000
Blincyto for Acute Lymphoblast...	Blincyto (Resubmission)	Blinatumomab	pcodr_profund_blinatumomab_blincyto_all_resub.pdf pcodr_blinatumomab_blincyto_all_resub_fn_rec.pdf pcodr_blinatumomab_blincyto_all_resub_fn_cgr.pdf pcodr_blinatumomab_blincyto_all_resub_fn_egr.pdf pcodr_blinatumomab_blincyto_all_resub_in_rec.pdf pcodr_blinatumomab_blincyto_all_resub_pagfdk.pdf pcodr_blinatumomab_blincyto_all_resub_fdk_amgen.pdf pcodr_blinatumomab_blincyto_all_resub_coi_ptgrp.pdf pcodr_blinatumomab_blincyto_all_resub_coi_clinician.pdf	Acute Lymphoblastic Leukemia (ALL)	Reimburse with clinical criteria and/or conditions	Complete	Feb 24, 2017	Aug 31, 2017	PC0097-000
Opdivo for Squamous Cell Carci...	Opdivo	Nivolumab	pcodr_profund_nivolumab_opdivo_scchn.pdf pcodr_nivolumab_opdivo_scchn_fn_rec.pdf pcodr_nivolumab_opdivo_scchn_fn_cgr.pdf pcodr_nivolumab_opdivo_scchn_fn_egr.pdf pcodr_nivolumab_opdivo_scchn_in_rec.pdf pcodr_nivolumab_opdivo_scchn_pagfdk.pdf pcodr_nivolumab_opdivo_scchn_fdk_bms.pdf pcodr_nivolumab_opdivo_scchn_coi_ptgrp.pdf	Squamous Cell Carcinoma of Head and Neck (SCCHN)	Reimburse with clinical criteria and/or conditions	Complete	Jan 31, 2017	Aug 31, 2017	PC0095-000
Blinatumomab (Blincyto) for Ac...	Blincyto	Blinatumomab	pcodr_profund_blinatumomab_blincyto_all_pediatric.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_rec.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_cgr.pdf pcodr_blinatumomab_blincyto_all_pediatric_fn_egr.pdf pcodr_blinatumomab_blincyto_all_pediatric_in_rec.pdf pcodr_blinatumomab_blincyto_all_pediatric_pagfdk.pdf pcodr_blinatumomab_blincyto_all_pediatric_fdk_amgen.pdf pcodr_blinatumomab_blincyto_all_pediatric_coi_ptgrp.pdf pcodr_blinatumomab_blincyto_all_pediatric_coi_clinician.pdf	Acute Lymphoblastic Leukemia (pediatric)	Reimburse with clinical criteria and/or conditions	Complete	Feb 24, 2017	Aug 23, 2017	PC0099 -000
Keytruda for Advanced Non-Smal...	Keytruda	Pembrolizumab	PembrolizumabKeytruda_AdvancedNSCLCfirstline10101_ProvFunding.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_cgr.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fn_egr.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_in_rec.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_pagfdk.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_fdk_merck.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_ptgrp.pdf pcodr_pembrolizumab_keytruda_nsclc_1stln_coi_clinician.pdf	Advanced non-small cell lung carcinoma (first line)	Reimburse with clinical criteria and/or conditions	Complete	Dec 12, 2016	Aug 23, 2017	PC0101-000
Eliglustat	Cerdelga	Eliglustat	cdr_SR0511_Cerdelga.pdf SR0511_complete_Cerdelga_Jul_28_17_e.pdf SR0511_Cerdelga_CL_Report_e.pdf SR0511_Cerdelga_PE_Report_e.pdf SR0511_Cerdelga_PI_Submissions.pdf	Gaucher disease	Reimburse with clinical criteria and/or conditions	Complete	Jan 20, 2017	Jul 26, 2017	SR0511-000
abobotulinumtoxinA	Dysport Therapeutic	abobotulinumtoxinA	cdr_SR0512_Dysport_Therapeutic.pdf SR0512_complete_Dysport_Therapeutic_Jul_28_17_e.pdf SR0512_Dysport_Therapeutic_CL_Report_e.pdf SR0512_Dysport_Therapeutic_PE_Report_e.pdf SR0512_Dysport_Therapeutic_PI_Submissions.pdf	Cervical dystonia	Reimburse with clinical criteria and/or conditions	Complete	Jan 31, 2017	Jul 26, 2017	SR0512-000
Obeticholic Acid	Ocaliva	Obeticholic Acid	cdr_SR0509_TBC.pdf SR0509_complete_Ocaliva_Jul_27_17_e.pdf SR0509_Ocaliva_CL_Report_e.pdf SR0509_Ocaliva_PE_Report_e.pdf SR0509 Ocaliva_PI_Submissions.pdf	Primary Biliary Cholangitis	Reimburse with clinical criteria and/or conditions	Complete	Dec 22, 2016	Jul 25, 2017	SR0509-000
Glatiramer acetate	Glatect	Glatiramer acetate	cdr_SE0510_Glatect.pdf SE0510_complete_Glatect-Jul-27-e.pdf SE0510_Glatect _PI_Submissions.pdf SE0510_Glatect_SENB_Complex_Drug_Submission_Report.pdf	Relapsing Remitting Multiple Sclerosis (RRMS)	Reimburse with clinical criteria and/or conditions	Complete	Jan 20, 2017	Jul 25, 2017	SE0510-000
Etanercept	Erelzi	Etanercept	cdr_SE0513_TBC.pdf SE0513_complete_Erelzi_Jul_28_17_e.pdf SE0513_Erelzi_SEB_Report.pdf SE0513_Erelzi_PI_Submissions.pdf	Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis	Reimburse with clinical criteria and/or conditions	Complete	Feb 2, 2017	Jul 25, 2017	SE0513-000
Ninlaro for Multiple Myeloma –...	Ninlaro	Ixazomib	pcodr_provfund_ixazomib_ninlaro_mm.pdf pcodr_ixazomib_ninlaro_mm_fn_rec.pdf pcodr_ixazomib_ninlaro_mm_fn_cgr.pdf pcodr_ixazomib_ninlaro_mm_fn_egr.pdf pcodr_ixazomib_ninlaro_mm_in_rec.pdf pcodr_ixazomib_ninlaro_mm_pagfdk.pdf pcodr_ixazomib_ninlaro_mm_fdk_takeda.pdf pcodr_ixazomib_ninlaro_mm_ptfdk.pdf pcodr_ixazomib_ninlaro_mm_clnfdk.pdf pcodr_ixazomib_ninlaro_mm_coi_mmc.pdf pcodr_ixazomib_ninlaro_mm_coi_cln.pdf	Multiple Myeloma	Do not reimburse	Complete	Dec 16, 2016	Jun 29, 2017	PC0088-000
Daclizumab beta	Zinbryta	Daclizumab beta	cdr_SR0508_Zinbryta.pdf SR0508_compelte_Zinbryta_Jun-22-17_e.pdf SR0508_Zinbryta_CL_Report.pdf SR0508_Zinbryta_PE_Report.pdf SR0508_Zinbryta_PI_Submissions.pdf	Multiple Sclerosis, relapsing-remitting	Reimburse with clinical criteria and/or conditions	Complete	Dec 20, 2016	Jun 20, 2017	SR0508-000
Gazyva for Follicular Lymphoma...	Gazyva	Obinutuzumab	pcodr_profund_obinutuzumab_gazyva_fl.pdf pcodr_obinutuzumab_gazyva_fl_fn_rec.pdf media:document:b525feb5-dfab-4fab-9329-39565d03e75a media:document:e96c2560-fd09-4813-ac09-a3cef1e32514 pcodr_obinutuzumab_gazyva_fl_fn_cgr.pdf pcodr_obinutuzumab_gazyva_fl_fn_egr.pdf pcodr_obinutuzumab_gazyva_fl_in_rec.pdf pcodr_obinutuzumab_gazyva_fl_pagfdk.pdf pcodr_obinutuzumab_gazyva_fl_fdk_roche.pdf pcodr_obinutuzumab_gazyva_fl_ptfdk.pdf pcodr_obinutuzumab_gazyva_fl_coi_pt.pdf	Follicular Lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Nov 4, 2016	Jun 2, 2017	PC0091-000
Edoxaban	Lixiana VTE	Edoxaban	cdr_SR0499_Lixiana_VTE.pdf SR0499_complete_Lixiana_VTE_May_29_17_e.pdf SR0499_Lixiana_VTE_CL_Report.pdf SR0499_Lixiana_VTE_PE_Report.pdf	Venous thromboembolism, treatment and recurrence prevention.	Reimburse with clinical criteria and/or conditions	Complete	Sep 9, 2016	May 25, 2017	SR0499-000
emtricitabine/rilpivirine/ ten...	Odefsey	emtricitabine/rilpivirine/ tenofovir alafenamide	cdr_SR0507_TBC.pdf SR0507_complete_Odefsey- May-25-17_e.pdf SR0507_Odefsey_Combined_Report.pdf SR0507_Odefsey_PI_Submissions.pdf	HIV-1 infection	Reimburse with clinical criteria and/or conditions	Complete	Nov 24, 2016	May 25, 2017	SR0507-000
Ivabradine	Lancora	Ivabradine	cdr_SR0506_Lancora.pdf SR0506_complete_Lancora-Jun15-17_e.pdf SR0506_ Lancora_CL_Report.pdf SR0506_ Lancora_PE_Report.pdf SR0506_Lancora_PI_Submissions.pdf	Heart failure, NYHA class II or III	Reimburse with clinical criteria and/or conditions	Complete	Nov 8, 2016	May 24, 2017	SR0506-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 526 - 550 of 600

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Non-pharmacological and Pharmacological Intervention for Smoking Cessation Programs in Youth: A Review of Clinical Effectiveness and Guidelines	RC1235 Smoking Cessation Youth Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1235-000
Orthotic Bracing or Splinting of Upper Extremities in Patients with Chronic, Non-Cancer Pain: A Review of Clinical Effectiveness	RC1252 Splinting for Upper Extremity Pain Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1252-000
Magnetic Localization System for Sentinel Lymph Node Biopsy: A Review of the Diagnostic Accuracy, Cost-Effectiveness, and Guidelines	RC1249 Magtrace Final.pdf	Mar 2, 2020	Summary with Critical Appraisal	Completed	RC1249-000
Prenatal and Postnatal Home Visiting Programs for Parents, Newborns, and Babies: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1243 Home Visit Programs Final.pdf	Feb 26, 2020	Summary with Critical Appraisal	Completed	RC1243-000
Lurasidone Hydrochloride for Bipolar Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1244 Lurasidone for BD Final.pdf	Feb 26, 2020	Summary with Critical Appraisal	Completed	RC1244-000
Pilocarpine for Xerostomia and Xerophthalmia in Sjögren’s Syndrome: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1227- Pilocarpine for SIX Final.pdf	Feb 26, 2020	Summary with Critical Appraisal	Completed	RC1227-000
Palivizumab For Infection Prevention in Inuit Infants: A Review of the Clinical Effectiveness and Cost-Effectiveness	RC1217 Palivizumab Prophylaxis Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1217-000
Ondansetron and Oral Rehydration Therapy in Pediatric Patients with Dehydration: Clinical Effectiveness	RC1242 ondansetron Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1242-000
Prostaglandin Analogues for Ophthalmic Use: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1248 Pros Analogues Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1248-000
Quetiapine for Major Depressive Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1233 Quetiapine for MDD Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1233-000
Combination Use of Ivabradine with Sacubitril/Valsartan: A Review of Clinical Effectiveness and Guidelines	RC1247 Ivabradine Sacubitril Valsartan Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1247-000
Intraosseous Contrast Media Injection for Computed Tomography Scan or Magnetic Resonance Imaging: A Review of Clinical Effectiveness and Guidelines	RC1234 Intraosseous Devices Final.pdf	Feb 24, 2020	Summary with Critical Appraisal	Completed	RC1234-000
Artificial Intelligence for Classification of Lung Nodules: A Review of Clinical Utility, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines	RC1228 AI for Lung Nodules Final.pdf	Feb 18, 2020	Summary with Critical Appraisal	Completed	RC1228-000
Clozapine Initiation for Schizophrenia: A Review of Clinical Effectiveness and Guidelines	RC1229 Clozapine Initiation Final.pdf	Feb 18, 2020	Summary with Critical Appraisal	Completed	RC1229-000
Pilocarpine for Radiotherapy-Induced Dry Mouth and Dry Eyes: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1226 Pilocarpine for RIX Final.pdf	Feb 18, 2020	Summary with Critical Appraisal	Completed	RC1226-000
Pharmacogenomic Testing in Depression: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1232 RxGx testing depression Final.pdf	Feb 18, 2020	Summary with Critical Appraisal	Completed	RC1232-000
Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis	he0022-major-depressive-disorder-critical-appraisal.pdf	Feb 18, 2020	Technology Review	Completed	HE0022-000
Physical Activity for Chronic Osteoarthritic Knee Pain: A Review of Clinical Effectiveness	RC1230 Physical Activity for KOA Final.pdf	Feb 17, 2020	Summary with Critical Appraisal	Completed	RC1230-000
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy: A Critical Appraisal of the MENTOR Study	ha0001-mentor-study-focused-crititcal-appraisal.pdf	Jan 23, 2020	Technology Review	Completed	HA0001-000
Utilization of Innovator Biologics and Biosimilars for Chronic Inflammatory Diseases in Canada: A Provincial Perspective		Jan 21, 2020			HO0007-HE0024
Internet-Based Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder		Jan 20, 2020	Optimal Use	Completed	OP0537-000
csDMARDS for Rheumatoid Arthritis	op0539-cs-dmards-for-ra-fca-correction.pdf	Jan 16, 2020	Technology Review	Completed	HE0029-000
Elevated Vacuum Suspension Systems for Adults with Amputation: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1224 EVSS Final.pdf	Jan 15, 2020	Summary with Critical Appraisal	Completed	RC1224-000
Drug Therapies for the Long-Term Prophylaxis of Hereditary Angioedema Attacks	ob0007-hae-prophylaxis-redacted.pdf	Dec 19, 2019		Completed	OB0007-000
Pilocarpine for Medication-induced Dry Mouth and Dry Eyes: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines	RC1225 Pilocarpine for MIX Final.pdf	Dec 11, 2019	Summary with Critical Appraisal		RC1225-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 526 - 550 of 2132

Please scroll or swipe to the right to view the full content.

Title	Description	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Pathology Implementation Advice Panel: Guidance for Reporting Diagnostic Classifications for Breast Cancer		Pathology Implementation Advice Panel: Guidance for Reporting Diagnostic Classi…	Dec 7, 2023	Health Technology Review	Technology Review	Completed	HC0070-000
HR+ HER2- Breast Cancer and Triple Negative Breast Cancer, with inclusion of HER2 Low Breast Cancer		Final Report	Dec 7, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0033-000
Technologies to Increase Freedom for People Living With Dementia		Technologies to Increase Freedom for People Living With Dementia	Dec 6, 2023	Horizon Scan	Emerging Health Technologies	Completed	EH0113-000
CADTH Pharmaceutical Reviews Update — Issue 42			Nov 30, 2023	Reimbursement Review	Pharmaceutical Review Update
zanubrutinib		Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Nov 29, 2023	Reimbursement Review		Complete	PC0310-000
An Analysis of Demographic and Utilization Patterns of Patients Accessing Emergency Departments in Canada		Emergency Department Overcrowding: Utilization Analysis Emergency Department Overcrowding: Utilization Analysis: Methods Document	Nov 28, 2023	Health Technology Review	Technology Review	Complete	HC0061-000
Emergency Department Overcrowding in Canada: An Update		CADTH Guidance: Emergency Department Overcrowding Contributing Factors and Intervention Effectiveness Supporting Information: Factors and Intervention Effectiveness Multistakeholder Dialogue Protocol: Contributing Factors and Intervention Effectiveness Evidence Preview: Factors and Intervention Effectiveness	Nov 24, 2023	Health Technology Review	Optimal Use	Completed	OP0553-000 - RE0044-000
clascoterone			Nov 17, 2023	Reimbursement Review		Withdrawn	SR0786-000
belzutifan		Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Nov 16, 2023	Reimbursement Review		Complete	PC0309-000
Vital Signs Monitoring Sticker		Vital Signs Monitoring Sticker	Nov 14, 2023	Horizon Scan	Health Technology Update	Completed	EN0048-000
dabrafenib trametinib			Nov 10, 2023	Reimbursement Review		Cancelled	PC0337-000
Biologics in Plaque Psoriasis		Streamlined Drug Class Review – Final Recommendation and Reasons Responses to Questions From the Drug Programs Updated CADTH Reimbursement Recommendations CADTH Review - Final Summary Report	Nov 9, 2023	Reimbursement Review	Streamlined Drug Class Review	Complete	TS0001-000
Case Carts in Surgical Settings		Case Carts in Surgical Settings	Nov 8, 2023	Health Technology Review	Rapid Review	Completed	RC1512-000
Routine Dental Polishing for Oral Health		Routine Dental Polishing for Oral Health	Nov 8, 2023	Health Technology Review	Rapid Review	Completed	RC1517-000
Intrathecal Drug Delivery Systems for Cancer Pain			Nov 6, 2023	Health Technology Review	Technology Review	Completed	HC0058-000
Buprenorphine Naloxone Film versus Tablets for Opioid Use Disorder	CADTH's Health Technology Review identifies and summarizes literature comparing the effectiveness and cost-effectiveness of sublingual buprenorphine-naloxone films versus tablets.	Buprenorphine Naloxone Film versus Tablets for Opioid Use Disorder	Nov 6, 2023	Health Technology Review	Rapid Review	Completed	RC1513-000
Intraocular Lenses for Cataract Surgery		Intraocular Lenses for Cataract Surgery	Nov 6, 2023	Health Technology Review	Rapid Review	Completed	RC1515-000
Anti–Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration		Anti–Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration	Nov 6, 2023	Health Technology Review	Rapid Review	Completed	RC1510-000
Supplemental Screening Modalities for People With Dense Breasts			Nov 1, 2023	Health Technology Review	Technology Review	Completed	HC0026-000
Chronic Lymphocytic Leukemia		Final Report	Oct 27, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0035-000
Prostate Cancer		Final Report	Oct 27, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0034-000
ravulizumab		Recommendation and Reasons Clinical, Pharmacoeconomic and Ethics combined Report Stakeholder feedback on Draft Recommendation	Oct 27, 2023	Reimbursement Review		Complete	SR0765-000
Hyperbaric Oxygen Therapy: An Emerging Therapy for Post–COVID-19 Condition	CADTH’s Horizon Scan examines hyperbaric oxygen therapy as a treatment to help resolve prominent symptoms of post-COVID-19 condition, such as fatigue and brain fog.	Hyperbaric Oxygen Therapy: An Emerging Therapy for Post–COVID-19 Condition	Oct 27, 2023	Horizon Scan	Health Technology Update	Completed	EN0050-000
Refractive Laser Surgery for Vision Conditions		Refractive Laser Surgery for Vision Conditions	Oct 26, 2023	Health Technology Review	Rapid Review	Completed	RC1514-000
New and Emerging Interventions to Alleviate Emergency Department Overcrowding	CADTH's Horizon Scan captures more than 80 new and emerging interventions to alleviate emergency department overcrowding. The interventions are organized into 5 broad categories of factors that contribute to emergency department overcrowding.	New and Emerging Interventions to Alleviate Emergency Department Overcrowding	Oct 25, 2023	Horizon Scan	Health Technology Update	Completed	EN0051-000